79 related articles for article (PubMed ID: 4194682)
1. [Double blind test of PPC for prostatic hyperplasia].
Shimaya M; Sugiura H
Hinyokika Kiyo; 1970 May; 16(5):231-6. PubMed ID: 4194682
[No Abstract] [Full Text] [Related]
2. [Clinical effect of PPC for the palliative treatment of benign prostatic hypertrophy].
Ishigami J; Kuroda K
Hinyokika Kiyo; 1969 Jan; 15(1):68-75. PubMed ID: 4180035
[No Abstract] [Full Text] [Related]
3. [Clinical application of "PPC" to prostatic hypertrophy and others].
Sugiura H; Shimaya M
Hinyokika Kiyo; 1969 Jun; 15(6):450-3. PubMed ID: 4185864
[No Abstract] [Full Text] [Related]
4. [The conservative treatment of prostatic hypertrophy with Paraprost].
Aito K; Watsubo E
Hinyokika Kiyo; 1972 Jan; 18(1):41-4. PubMed ID: 4112552
[No Abstract] [Full Text] [Related]
5. [BPH pharmacotherapy (miscellaneous)].
Okada H
Nihon Rinsho; 2002 Dec; 60 Suppl 11():367-72. PubMed ID: 12599602
[No Abstract] [Full Text] [Related]
6. [Clinical application of PPC for prostatic hypertrophy and female cystopathy].
Nishimura Y; Ikeda T
Hinyokika Kiyo; 1969 Feb; 15(2):127-34. PubMed ID: 4181094
[No Abstract] [Full Text] [Related]
7. [Use of amino acids as a combination in the treatment of prostatic hypertrophy].
Menéndez Fernández H; Castillo Vergara P; Hilario García Marcos J; Romero Gil JR
Arch Esp Urol; 1988 Sep; 41(7):495-9. PubMed ID: 2468315
[No Abstract] [Full Text] [Related]
8. Clinical evaluation of effects of prazosin in patients with benign prostatic obstruction. A double-blind, multi-institutional, Paraprost-controlled study.
Yamaguchi O; Shiraiwa Y; Kobayashi M; Yokota T; Ohinata M; Aoki H; Tsuzuki T; Ohori M
Urol Int; 1990; 45 Suppl 1():40-6. PubMed ID: 1690481
[TBL] [Abstract][Full Text] [Related]
9. Palliative treatment of benign prostatic hypertrophy; value of glycine-alanine-glutamic acid combination.
FEINBLATT HM; GANT JC
J Maine Med Assoc; 1958 Mar; 49(3):99-101 passim. PubMed ID: 13514330
[No Abstract] [Full Text] [Related]
10. [Clinical study of a phytosterol extract of Prunus arborea and 3 amino acids: glycine, alanine and glutamic acid].
Cuervo Blanco E; Francia Bengoechea A; Fraile Gómez B
Arch Esp Urol; 1978; 31(1):97-8. PubMed ID: 697415
[TBL] [Abstract][Full Text] [Related]
11. [Effects of urea-cycle amino-acid and glutamic acid on hyperammonemia].
Kurimura O; Seki K; Omura I; Miyazaki H; Okuhiro S
Iryo; 1966 Apr; 20(4):305-9. PubMed ID: 5974187
[No Abstract] [Full Text] [Related]
12. [The effectiveness of beta-sitosterol in treatment of benign prostatic hyperplasia].
Senge T; Windeler J; Berges RR; Trampisch HJ
Urologe A; 1995 Mar; 34(2):130-1. PubMed ID: 7538710
[No Abstract] [Full Text] [Related]
13. Morning versus evening dosing with doxazosin in benign prostatic hyperplasia: pharmacokinetics, efficacy and safety.
Kirby RS
Int J Clin Pract; 1998 Mar; 52(2):75-7. PubMed ID: 9624784
[No Abstract] [Full Text] [Related]
14. [Amino acid therapy for hypertrophy of the prostate].
Shiga H; Kumamoto E; Imamura A
Hinyokika Kiyo; 1968 Aug; 14(8):625-32. PubMed ID: 4178205
[No Abstract] [Full Text] [Related]
15. Maintenance of clinical efficacy with finasteride therapy for 24 months in patients with benign prostatic hyperplasia. The Finasteride Study Group.
Stoner E
Arch Intern Med; 1994 Jan; 154(1):83-8. PubMed ID: 7505563
[TBL] [Abstract][Full Text] [Related]
16. Finasteride in the treatment of benign prostatic hyperplasia.
Ekman P; Andersen JT; Wolf H
Acta Urol Belg; 1996 Mar; 64(1):IX-XII. PubMed ID: 8659328
[TBL] [Abstract][Full Text] [Related]
17. [Conservative therapy of prostatic adenoma as well as prostatitis with beta-sitosterol prostate capsules].
Karcher G
Med Welt; 1982 Dec; 33(48):1763-6. PubMed ID: 6185822
[No Abstract] [Full Text] [Related]
18. A randomized double-blind study assessing 4 versus 8 mg. doxazosin for benign prostatic hyperplasia.
MacDiarmid SA; Emery RT; Ferguson SF; McGuirt-Franklin R; McIntyre WJ; Johnson DE
J Urol; 1999 Nov; 162(5):1629-32. PubMed ID: 10524884
[TBL] [Abstract][Full Text] [Related]
19. Combined extracts of Urtica dioica and Pygeum africanum in the treatment of benign prostatic hyperplasia: double-blind comparison of two doses.
Krzeski T; Kazón M; Borkowski A; Witeska A; Kuczera J
Clin Ther; 1993; 15(6):1011-20. PubMed ID: 7509261
[TBL] [Abstract][Full Text] [Related]
20. Alfuzosin in the treatment of benign prostatic hyperplasia: effects on symptom scores, urinary flow rates and residual volume. A multicentre, double-blind, placebo-controlled trial. ALFECH Study Group.
Hansen BJ; Nordling J; Mensink HJ; Walter S; Meyhoff HH
Scand J Urol Nephrol Suppl; 1994; 157():169-76. PubMed ID: 7524141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
